Jain, Rakesh, PhD

Rakesh_jain
Phone:
Email:

Tumor Vessels and Microenvironment: Bench to Bedside and Back

A solid tumor is an organ composed of cancer cells and host stromal cells, which are nourished by the vasculature and embedded in an extra-cellular matrix. The interaction among these cells, the surrounding matrix, and the local cellular microenvironment influences the expression of certain genes, whose products control the pathophysiological characteristics of the tumor, govern tumor progression, and affect the tumor’s response to various therapies. Blood and lymphatic vessels also serve as conduits for metastatic spread. The over arching goal of our research is to dissect the pathophysiology of the vascular and extra-vascular components of tumors, to determine the role of tumor-host interactions in tumor biology, and ultimately to translate this knowledge into improved cancer detection, prevention, and treatment in humans.

To unravel the complex biology of tumors, we have developed an array of imaging technologies, mathematical models, and sophisticated animal preparations. These include multiphoton microscopy and genetically engineered mice with surgically implanted transparent windows, which permit the in vivo visualization of gene expression and function in tumors and their surrounding host stroma. This undertaking has provided unprecedented molecular, cellular, anatomical, and functional insights into the vascular, interstitial and cellular barriers to cancer treatment.

Our laboratory found that high interstitial pressure is a universal characteristic of solid tumors, and that it can impair the delivery of molecular medicine within tumors, induce peri-tumor edema and contribute to lymphatic metastasis. We have identified the mechanisms underlying this elevated pressure: high vascular permeability, lack of functional lymphatics, and mechanical stress generated by tumor growth. Overexpression of the lymphangiogenic factor VEGF-C increases lymph node metastasis, but does not increase lymphatic function or decrease the interstitial pressure. However, judicious application of antiangiogenic agents can lower the pressure and improve the delivery and efficacy of various cancer treatments. To gain a deeper insight of tumor microenvironment, we measured interstitial convection, diffusion, and binding using photobleaching, and pO2 and pH profiles around individual tumor vessels using phosphorescence quenching and ratio imaging. We proposed the novel hypothesis that the anomalous assembly of the collagen network can prevent the penetration of therapeutic agents in tumors, and showed that the hormone relaxin, bacterial collagenase, MMP1/8 and anti-hypertensive drugs can improve drug distribution by modifying this network.

Our finding that angiogenic molecules regulate adhesion molecules on the vasculature provided the first link between the disparate fields of angiogenesis and adhesion, and revealed a novel mechanism by which tumors evade immune recognition. In collaboration with Dr. Brian Seed, we discovered that cancer cells co-opt the host stromal cells and entice them to produce pro- and anti-angiogenic growth factors. By revealing that host cells are not passive bystanders, but active participants in tumor angiogenesis, growth, metastasis, and therapeutic response, our laboratory provided a rational basis for combining Herceptin with VEGF blockade for the treatment of breast cancer – a concept that led to a clinical trial.

Our work has revealed that the malfunction of the vascular and extravascular compartments in solid tumors often thwarts the effectiveness of both conventional and novel therapies. Our laboratory is most celebrated for a new hypothesis that antiangiogenic therapy can “normalize” the abnormal tumor vasculature and improve both the delivery and efficacy of therapeutics. We have validated this concept in rectal carcinoma and glioblastoma patients receiving antiangiogenic therapy and in the process, discovered potential biomarkers of tumor escape from these therapies. Now we are exploring novel strategies to expand the window of normalization and seeking potential biomarkers for tailoring therapies to individuals.

By integrating principles from physiology, pharmacology, immunology, and molecular biology, our laboratory has developed mathematical models of drug delivery and pathophysiological processes in solid tumors. These modeling tools have allowed us to extract simple, important principles that should spark the development of novel diagnostic and therapeutic strategies.

Click here for Dr. Jain’s CV

Selected Publications (from total of 689)

Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, Chung E, Clark JW, Willett CG, Luster AD, Yun SH, Langer R, Anderson DG, Padera TP, Jain RK, Fukumura D
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.
J Clin Invest. 2017;127(8):3039-3051 - PMID: 28691930 - PMCID: PMC5531423
Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, Cai T, Clevers H, Swanton C, Nowak MA, Elledge SJ, Jain RK
Origins of lymphatic and distant metastases in human colorectal cancer.
Science. 2017;357(6346):55-60 - PMID: 28684519 - PMCID: PMC5536201
Askoxylakis V, Kodack DP, Ferraro GB, Jain RK
Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?
Breast Cancer Res Treat. 2017;165(2):467-468 - PMID: 28643019
Askoxylakis V, Arvanitis CD, Wong CSF, Ferraro GB, Jain RK
Emerging Strategies for Delivering Antiangiogenic Therapies to Primary and Metastatic Brain Tumors.
Adv Drug Deliv Rev. 2017;:ePub - PMID: 28648712
Levin VA, Chan J, Datta M, Yee JL, Jain RK
Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
J Neurooncol. 2017;:ePub - PMID: 28631191
Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK
Use of Angiotensin System Inhibitors is Associated with Immune Activation and Longer Survival in Non-Metastatic Pancreatic Ductal Adenocarcinoma.
Clin Cancer Res. 2017;:ePub - PMID: 28600474
David P. Kodack, Vasileios Askoxylakis, Gino B. Ferraro, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Z. Alexander Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Yongchul Song, Carlotta Costa, Kamila Naxerova, Christina S. F. Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima Tanboon, Dan G. Duda, C. Ryan Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Monica V. Estrada, Robert Schlegel, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Science Translational Medicine. 2017;9(391):eaal4682
Kapoor R, Srivastava N, Kumar S, Saritha RK, Sharma SK, Jain RK, Baranwal VK
Development of a recombinase polymerase amplification assay for the diagnosis of banana bunchy top virus in different banana cultivars.
Arch Virol. 2017;:ePub - PMID: 28500444
De Palma M, Jain RK
CD4(+) T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?
Immunity. 2017;46(5):773-775 - PMID: 28514684
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Sci Transl Med. 2017;9(391):ePub - PMID: 28539475
Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Sci Rep. 2017;7:44123 - PMID: 28276530 - PMCID: PMC5343435
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Cancer. 2017;123(11):1979-1988 - PMID: 28192597 - PMCID: PMC5444988
Mpekris F, Baish JW, Stylianopoulos T, Jain RK
Role of vascular normalization in benefit from metronomic chemotherapy.
Proc Natl Acad Sci U S A. 2017;114(8):1994-1999 - PMID: 28174262 - PMCID: PMC5338413
Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, Jain RK, Garkavtsev I
Stress granule-associated protein G3BP2 regulates breast tumor initiation.
Proc Natl Acad Sci U S A. 2017;114(5):1033-1038 - PMID: 28096337 - PMCID: PMC5293063
Wang N, Jain RK, Batchelor TT
New Directions in Anti-Angiogenic Therapy for Glioblastoma.
Neurotherapeutics. 2017;14(2):321-332 - PMID: 28083806 - PMCID: PMC5398985
15